Back to today’s briefing

Story perspectives

Breakthroughs in Cancer Detection and Treatment Unveiled

1/22/2025

31 7

Summary

Story summary

Exact Sciences' Oncodetect test is making waves with its impressive ability to detect molecular residual disease and predict colorectal cancer recurrence, boasting remarkable sensitivity rates. In a breakthrough, NUS researchers have pinpointed DUSP6 as a crucial player in cancer growth, opening doors for new therapies. Meanwhile, Dogwood Therapeutics gears up for a Phase 2b trial of Halneuron® to combat chemotherapy-induced neuropathy.

1 of 1

Story summary

Exact Sciences' Oncodetect test is making waves with its impressive ability to detect molecular residual disease and predict colorectal cancer recurrence, boasting remarkable sensitivity rates. In a breakthrough, NUS researchers have pinpointed DUSP6 as a crucial player in cancer growth, opening doors for new therapies. Meanwhile, Dogwood Therapeutics gears up for a Phase 2b trial of Halneuron® to combat chemotherapy-induced neuropathy.